



## Molecular modeling of 5-Oxo-3-substituted pyrrolidine -2-carboxylic acid derivatives pure as protease inhibitors

Nagham M. Zeki <sup>1</sup>, Zaheda A. Najim <sup>2</sup>, Faris T. Abachi <sup>1\*</sup>

<sup>1</sup>Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, Iraq

<sup>2</sup>Department of Chemistry, College of Education for Pure Science, University of Mosul, Mosul, Iraq

*Received: 27-01-2018 / Revised Accepted: 28-02-2018 / Published: 11-03-2018*

### ABSTRACT

*Ab initio* molecular orbital theory with the HF/6-31G basis has been used to investigate the geometries and preferred conformations for L- proline, novel derivatives of pyrrolidine 2-carboxylic acid derivatives and a few N-acetyl derivatives. Fifteen products were tested and predicated their some physical parameters for the MM2 molecular mechanics program as well as protease inhibitors. Huckel's molecular orbital theory is a convenient method of expressing the energy levels generated by the *p*- orbitals of carbon atoms (HOMO& LUMO). The aim was designated to study the molecular docking at the gorge site and PAS of Protease inhibitors (PI) by the program MOE as well as predication of ADME/T. In conclusion, the selected compound of pyrrolidine -2- carboxylic acid derivative compound 9 show 100% inhibition of protease.

**Keywords:** *Ab initio*, protease inhibitors, ADME/T, BBB, MM2 molecular mechanics.

**Address for Correspondence:** Dr. Prof. Faris T. Abachi, BSc., MSc., PhD, Pharmaceutical Sciences, Department of Pharmaceutical Sciences, College of Pharmacy, University of Mosul, Iraq;

**How to Cite this Article:** Nagham M. Zeki, Zaheda A. Najim, Faris T. Abachi. Molecular modeling of 5-Oxo-3-substituted pyrrolidine -2-carboxylic acid derivatives pure as protease inhibitors. World J Pharm Sci 2018; 6(3): 110-118.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which allows adapt, share and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. 

## INTRODUCTION

Protease inhibitors (PI) are new class of drug that inhibit cleavage of protein into functional and structural, they play an important role in many diseases. Now, there is considerable interest in investigation the potential of angiotensin converting enzyme inhibitors, which are one of the ten front-line therapy for essential hypertension. Many other types of protease inhibitors are used as HIV viral protease, antithrombocin (II), Serine protease and Cysteine protease [1].

The aim of this study was to calculate and molecular modeling of 5-oxo (thio) -3-substituted pyrrolidine-2-carboxylic acid derivatives as new protease inhibitor agents using different theoretical methods. [2]The *Ab initio* methodology was employed for 3-D structure and estimate their minimized energy, charge [3], steric effects[4], chemical hardness ( $\eta$ ) [5], chemical potential ( $\mu$ ) and molecular philicity ( $\omega$ ) [6]. The target predications for single protein were derived from 3-D Swiss target predication reports [7]. All hypothetical agents were tested and obey to Lipinski rule [ 8 ], as well as to discuss some of thier physicochemical properties and ADME/T of low molecular weight compounds and finding pure inhibitors aganist protease.

## METHODOLOGY

### Calculation of Quantum parameters

**Molecular Modeling:** The molecular modeling for the 3-Oxo-3-substituted pyrrolidiny-2-carboxylic acid derivatives were performed by using chem-3D ultra 12 version (Cambridge soft corporation, Cambridge, MM, USA ) implemented with molecular orbital computations software and molecular dynamic computation software (MM2). These agents were designated as protease inhibitors using Swiss target prediction protocols[4].

**Computation Studies:** Quantum chemical calculations were performed using Gaussian 16 suite programs. The calculations were carried out at the Hartre-Fock energy level HF / 6-31G basis set and DFT/ B3LYP/6-31G. Initial geometry optimization was carried out using molecular mechanics by the MM2 force. The lower energy conformers were optimized to fine an appropriate geometry and calculate the physical properties of the compounds, HOMO, LUMO energy levels, heat of formations ( $H_f$ ), hardness ( $\eta$ ), electronic chemical potential ( $\mu$ ) and global philicity index ( $\omega$ )[7].

**HOMO & LUMO energy levels:** Huckel's molecular orbital theory is a convenient method of

expressing the energy levels generated by the p-orbitals of carbon atoms. Energies will be in units of  $\beta$  and  $\alpha$  where  $\alpha$  is the coulomb integral. The energy of  $\alpha$  can be arbitrarily standardized as zero. Then the lowest unoccupied molecular orbital (LUMO) and highest occupied molecular orbital (HOMO) can be identified. The molecular energy level with the same energy as  $\alpha$  is known as the nonbonding molecular orbital, the molecular energy level with a higher energy than  $\alpha$  is known anti bonding molecular orbital. The energy level diagram obtained is sometimes referred to as an energy level spectrum.

**Physical properties calculation:** Quantum mechanics calculation methods provide definitions of important universal concept of molecular structure stability and reactivity [2]. An approximation for absolute hardness ( $\eta$ ) was developed [2], as follows.

$$\eta = \frac{1}{2}(I - A) = \frac{1}{2}(E_{LUMO} - E_{HOMO}) \dots \dots \dots (1)$$

where (I) is the ionization energy, (A) the electron affinity. According to the Koopmen's theorem [3] the ionization energy and electron affinity can be expressed by the following relation:  
I = - E HOMO and A = - E LUMO

Where HOMO is the energy of the highest occupied molecular orbital and LUMO is the energy of the lowest unoccupied molecular orbital. A higher (or less -ve) HOMO energy corresponds to the more reactive molecule in reaction with electrophiles, while lower LUMO energy is essential for molecular reaction with nucleophiles [4]. The hardness corresponds to the gap between these two orbitals in the molecule and it measures the resistance of a molecule to a change in their electron distribution. The global electron affinity can also be used in combination with ionization energy to calculate another global reactivity descriptor, the electronic chemical potential ( $\mu$ ), which can be defined [2] as follows:

$$\mu = \frac{1}{2}(I + A) = \frac{1}{2}(E_{HOMO} + E_{LUMO}) \dots \dots \dots (2)$$

While the global philicity index ( $\omega$ ) can be evaluated using the electronic chemical potential ( $\mu$ ) and chemical hardness ( $\eta$ ) [5] as follow:

$$\omega = \frac{\mu^2}{2\eta} \dots \dots \dots (3)$$

**Physicochemical properties of 5-Oxo-3-substitued pyrrolidinyl-2- carboxylic acid derivatives:** Some physicochemical properties

were predicated with the free version of MedChem Designer log  $p$ , number of hydrogen atom donor (H-Do) or acceptor (H-Acc), violations to the rule of five ( $R_o^5$ ) [8]. The percentage of protease inhibitors including different enzymes were estimated using Molinspiration bioactivity score (2016) or Swiss target predication score (2013) [9].

**Molecular Docking:** Molecular docking (MD) is a computationally intensive structure-based virtual screening (SBVS) technique that generates and scores putative protease 1a 30 and organic small molecules complexes according to their calculated binding affinities using Mcule program. The crystal structure of the target was given [9], molecular docking automatically samples ligand conformations and protease-ligand interactions with a specified region of the protein surface were measured. It has been successfully used for identifying active compounds by filtering out those that do not fit into the binding sites. In this study, molecular docking was performed at the gorge site and PAS of Protease inhibitors (PI) by the program MOE. Also, the binding of an amino acid in the enzyme with different functional groups of pyrrolidino derivatives [10].

**ADME/TOX:** Absorption, distribution, metabolism, excretion and toxicity (ADMET) profile of FDA approved that the protease inhibitors drugs, poor pharmacokinetic properties are one of the main reasons for terminating the development of drug candidates [11]. Computed physicochemical properties associated with compounds that have good oral bioavailability, less or decrease toxicity and the capacity to be penetrate the BBB are key decision filter for CNS drug discovery [12]. For further evaluation by Lipinski's rule and some other physico-chemical filtering relevant for CNS activity. The more than 1000 compounds were further submitted to an *in silico* evaluation for bioavailability and blood brain barrier BBB penetration filter. Specifically, some key computed parameters that we examined as part of multiple property filter of lead compounds are toxicity, octanol/water partition coefficient (Log  $P$ ), total polar surface area (TPSA), BBB penetration and CNS activity can be expressed *in vivo* blood-brain barrier penetration (Concentration in the brain / concentration in blood) [13], to prioritize compounds with higher probabilities of possessing favorable tissue absorption distribution profiles, bioavailability and BBB penetration. On applying all the above mentioned properties [14].

The *in vitro* Caco-2 Permeability assay uses an established method for predicting the *in*

*in vivo* absorption of drugs across the gut wall by measuring the rate of transport of a compound across the Caco-2 cell line [15]. The Caco-2 cell line is derived from a human colon carcinoma. The cells have characteristics that resemble intestinal epithelial cells such as the formation of a polarised monolayer, well-defined brush border on the apical surface and intercellular junctions [16][17].

## RESULTS AND DISCUSSION

The computational approach is one of the newest and fastest developing techniques in pharmacokinetics, ADME (absorption, distribution, metabolism, excretion) evaluation, drug discovery and toxicity [18]. However, to date, the software packages devoted to ADME prediction [19], especially of metabolism, have not yet been adequately validated and still require improvements to be effective [20]. The organic chemical structure of studied compounds were depicted in Table (1) [21].

The values of chemical hardness, chemical potential and global philicity were calculated using equation (1, 2, 3) respectively and tabulated in table (2) for DFT method and table (3) for HF method [22]. The general structure of pyrrolidine derivative figure 1 [1&2].




Fig 1: General Structure of Pyrrolidine Derivatives




Fig. 2. Complex structure between compound 9 (Ligand) with  $Zn^{+2}$

The results were listed in (Tables 2&3) respectively, and the values of the calculated properties in both methods were identical. It was noted that compound no.9 gave the lowest values for chemical hardness and philicity and highest value of chemical potential [3]. Fifteen compounds as 5-oxo-3-substituted pyrrolidine-2-carboxylic acid derivatives were designated and calculate some parameters as protease inhibitors using different programs and software. Our results were explained a four structures that can inhibited the Protease and demonstrate the most characteristic ligand-protein interactions through docking study. In general, it may be evidenced the process of inhibitors takes upon an unfolded shape and form a bridge between the 'anionic' (Tyr59) and 'peripheral' (Trp42) sites of 1a<sub>30</sub>protease [9]. Some calculated QSAR properties of the compounds at MM2 level were listed in (table 2). These observation parameters are charge, total energy, heat of formation, total dipole moment, frontier molecular orbital energy gap (calculated as LUMO-HOMO energy difference), ionization potential, polarizability, surface area, and volume [2][6]. All suggested compounds are in ground state not in excited state.

The logarithm of the partition coefficient  $\log P$  give the information about the solubility of these compounds whether it is hydrophilic or hydrophobic molecule. If the  $\log P$  value is positive, the molecule will be hydrophobic and more soluble in the organic solvents. If the  $\log P$  value is negative, the molecule will be hydrophilic and more soluble in aqueous buffer[23].

Most modeling compounds were obey Lipinski rule, the introduction of acetyl group ( $\text{CH}_3\text{CO}-$ ) at nitrogen of pyrrolidine ring can play an important role by increase potency towards inhibition of protease enzyme as shown in( tables 3&4) respectively. The docking of compound 9 with 1a<sub>30</sub> protease show good affinity and lowest energy figure 3[9][10]. The enzyme-based models have been useful in rationalizing the QSAR models generated in order to understand further the Protease-inhibitor interactions [11]. Such information available from QSAR [12][13], and enzyme-docking models used successfully to predict more potent analogues within a particular series [14][15].

The expected proposed mechanism can explain via the binding of  $\text{Zn}^{+2}$  ion with compound 9 to form a complex as shown in( figure2) and show 100% as protease inhibitor( table 1). The sulphhydryl (SH) group act as a strong chelating moiety with the zinc

ion. Consequently, the sulfhydryl group can show adverse effect, which were the same as those caused by mercapto-containing captopril [16].









This postulation that proline was esterified with glycine as spacer, then the  $\text{Zn}^{+2}$  will form a complex with the sulfhydryl group ( $-\text{SH}$ ) and carboxylic acid group ( $-\text{COOH}$ ) of the compound 9 (Ligand) and the expected complex [ $\text{Zn}^{+2}\cdot\text{L}\cdot 2\text{H}_2\text{O}$ ] as shown in (table 2) (figure 2). Our initial goal back in revolutionize ADME screening and to produce large quantities of standardized high quality data for predictive modeling purposes and for delivering results to clients to help them make decisions on how to progress their compounds. The ideal oral drug will be rapidly and completely absorbed from the alimentary canal and will find its way directly and specifically to its site of action. It will not bind to or interact with related receptors, and it will not bind non-specifically to passing serum proteins[21]. By replacing R group with beta-lactam ring compounds 12-15 were listed in (table 3), and expected to decrease their potency towards inhibition of protease and increase their toxicity. The predication of ADME/Tparameters were listed in (table 4). Compound 9 show no blood brain barrier as compare with other compounds and can't pass to the central nerve system. While, this compound was showed normal permeability and negative carcinogenicity in rat [22] as shown in (table 4).





Finally, numerous methods have been used for the selected organic compound 1-15 to predict the molecular modelling using different parameters. Among them, Caco2-cell model has been recommended as a reliable *in vitro* model for the prediction of oral drug absorption [20]. In distribution, blood brain barrier (BBB) penetration can give information of therapeutic drug in the central nervous system (CNS), plasma protein binding model in its disposition and efficacy [10][23].

## CONCLUSION

The information derived from the molecular modeling displays are useful in molecularly designing new potential protease inhibitor agent. The 5-oxo-3-substituted pyrrolidine-2-carboxylic acid derivatives show different activities against protease. Quantum chemical calculations were performed using Gaussian 16 suite programs and software as well as the predication of ADME/TOX parameters, only compound 9 was showed pure protease inhibitor. Our postulation that the functional groups ( $-\text{SH}$ ,  $-\text{COOH}$ ) will form a



4	 <p>4-methyl-5-oxopyrrolidine-2-carboxylic acid</p>	186.19	-0.60	2	2	143.05	Obey	0
4a	 <p>1-acetyl-5-hydroxy-4-methylpyrrolidine-2-carboxylic acid</p>	187.19	-0.46	2	2	77.84	Obey	80
5	 <p>3-ethyl-5-oxopyrrolidine-2-carboxylic acid</p>	199.21	-0.09	2	2	157.07	Obey	0
6	 <p>4-ethyl-5-oxopyrrolidine-2-carboxylic acid</p>	199.21	-0.09	2	2	157.07	Obey	0
7	 <p>2-(nitroxy)ethyl 5-oxopyrrolidine-2-carboxylate</p>	218.16	-2.83	2	2	219.06	Obey	0
8	 <p>2-hydroxyethyl 5-oxopyrrolidine-2-carboxylate</p>	173.17	-1.48	3	2	173.06	Obey	0
9	 <p>methyl 1-acetyl-3-(2-(2-benzyl-3-mercaptopropanamido)acetoxy)-5-oxopyrrolidine-2-carboxylate</p>	422.12	1.94	3	5	130.08	<b>Obey</b>	<b>100</b>
10	 <p>1-acetyl-3-(2-(2-benzyl-3-mercaptopropanamido)acetoxy)-5-oxopyrrolidine-2-carboxylic acid compound with ethene (1:1).((</p>	421.47	0.40	3	5	135.80	Obey	87

11	 <p>-3-(2-(2-benzyl-3-mercaptoopropanamido)acetoxy)-5-oxopyrrolidine-2-carboxylic acid compound with ethene (1:1).</p>	379.43	0.15	4	4	127.59	Obey	90
12	 <p>acetyl-2-carboxy-5-oxopyrrolidine-3-carboxamido)methyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid</p>	413.40	-0.64	3	8	161.39	Non	84
13	 <p>6-(1-acetyl-2-carboxy-5-oxopyrrolidine-3-carboxamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid</p>	412	-0.90	4	8	161.18	Non	60
14	 <p>3-(12-carboxyl-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-6-yl)carbamoyl-5-oxopyrrolidine-2-carboxylic acid</p>	370.38	-1.46	5	6	159.8	Obey	60
15	 <p>1-acetyl-3-(12-carboxyl-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptan-6-yl)carbamoyl-5-oxopyrrolidine-2-carboxylic acid</p>	412.42	-0.90	4	7	167.18	Obey	-

**Table 2 Calculated properties using Gaussian /DFT/B3LYP/6-31G**

No	S.E	Hf	LogP	cLogP	LogS	pKa
1	14.014	-398.51	-0.2148	-2.413	-0.1670	9.822 2.521
2	8.4632	-571.08	-0.7424	-2.413	0.0799	18.567 2.4070
3	12.2211	-524.40	-0.5474	-0.6279	-0.2244	3.8826 -
4	11.744	-524.09	-0.5759	-0.6279	-0.2032	10.0 3.844
5	12.2543	-544.73	<b>-0.0055</b>	<b>-0.0951</b>	-0.6385	9.00 3.844
6	11.7451	-542.09	-0.5759	-0.6279	-0.2032	10.0 3.844
7	12.3405	-784.73	-0.4165	-2.8325	-0.4992	- -
8	12.5558	-643.63	-1.2540	-1.4853	-0.2460	12.0 13.7834
<b>9</b>	<b>-8.3182</b>	<b>-1760.71</b>	<b>0.30132</b>	<b>1.93985</b>	<b>-2.4167</b>	<b>26</b> <b>3.0405</b>
Zn <sup>+2</sup> -L 2H <sub>2</sub> O	39.7064	----	0	0	0	----

**Table 2 calculation of other properties using Gaussian /DFT/B3LYP/6-31G**

No	HOMO/LOMO	H	$\mu$	$\Omega$
1	-0.2161/-0.0140	0.10105	-0.11505	0.0655
2	-0.0.397/0.1368	0.2669	-0.1301	0.031708
3	-0.2671/-0.0247	0.12119	-0.1459	0.08783
4	-2.680/-0.0242	0.1219	-0.1461	0.08755
5	-0.2566/-0.0371	0.10973	-0.14686	0.09828
6	-0.2603/-0.0241	0.11809	-0.14221	0.08562
7	-0.2537/-0.1083	0.07272	-.18102	0.2253
8	-0.2456/-0.0237	0.110925	-0.13467	0.08174
<b>9</b>	<b>-0.0629/0.0510</b>	<b>0.05695</b>	<b>-0.00595</b>	<b>0.00031</b>
Zn <sup>+2</sup> -L 2H <sub>2</sub> O	-0.3052/0.00047	0.15283	-0.15236	0.07723

S.E = Streic energy      Hf = Heat of formation.

**Table 3 Calculated properties using Gaussian / HF/ 6-31G**

No	H <sub>f</sub> (Hartree)	HOMO/LOMO	$\eta$	$\mu$	$\Omega$
1	-398.4462	-0.36311/0.16022	0.26165	-0.10144	0.01968
2	-473.2751	-0.3885/0.15885	0.27367	-0.11482	0.02408
3	-508.669	-0.42099/0.14555	0.28327	-0.13772	0.03347
4	-511.1521	-0.42166/0.14698	0.28432	-0.13734	0.03317
5	-550.2632	-0.40701/0.13749	0.27224	-0.13476	0.033353
6	-550.2952	-0.4031/0.14198	0.27254	-0.13056	0.031272
7	-828.4146	-0.40536/0.06447	0.23491	-0.17044	0.061831
8	-625.1188	-0.39396/0.15012	0.27204	-0.12192	0.02732
<b>9</b>	<b>-1752.729</b>	<b>-0.1955/0.1812</b>	<b>0.18835</b>	<b>-0.00715</b>	<b>0.000135</b>
Zn <sup>+2</sup> -L 2H <sub>2</sub> O	---	-0.32761/0.0005	0.16405	-0.16355	0.08152

**Table 4 Some ADME/TOXICITY parameters of compounds (1-15)**

No	BBB C.brain/C.blood	Caco-2 nm/s	Plasma permeability binding %	Log Kp cm/h	Carcinogenicity (Rat)
1	0.399054	20.392	83.379678	-4.20515	Negative
2	0.294675	18.7208	73.517428	-4.82636	Negative
3	0.383204	20.1792	60.271158	-3.86221	Postive
4	0.231434	19.1313	36.128900	-4.57658	Postive
5	0.372056	20.4917	14.126530	-3.51309	Postive
6	0.40214	20.497	27.547085	-3.5666	Postive
7	0.114893	13.4114	22.944148	-3.26301	Postive
8	0.280445	21.1094	18.660317	-4.81058	Negative
<b>9</b>	<b>0.047824</b>	20.9073	<b>61.071758</b>	-3.10683	<b>Negative</b>
10	0.0449153	20.8869	45.144161	-3.8866	Negative
11	0.051368	20.8486	61.51940	-3.99353	Negative
12	0.0441073	0.65291	52.80880	-4.89116	Postive
13	0.0376338	0.41886	23.00777	-5.25648	Positive
14	0.0351909	0.47966	18.8000	-5.29133	Negative
15	0.0372308	0.512417	29.0875	-5.23859	Positive

**REFERENCES**

- Flexner C. Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rational and clinical benefits. *Annu .Rev. Pharmacol.Toxicol* 2000; 40: 649-674.
- Nguyen LT et al. On the mechanism of metal colloid catalyzed hydrosilylation: proposed explanations for electronic effects and oxygen cocatalysis *J.Am.Chem.Soc* 1990; 121: 5992.
- Geerlings P, Deprof F, Langker W. Density Functional Theory : A Source of Chemical Concepts and a Cost-Effective Methodology for Their Calculatio. *Adv. Quantum Chem* 1999;33 : 303.
- Chandra K , Nguyen M T. Density functional approach to regiochemistry, activation energy, and hardness profile in 1, 3-dipolar cycloadditions. *J. Phys. Chem* 1998 ; A102 : 6181.
- De proff F et al. Chemical Modelling: Applications and Theory, *J.Am. Chem. Soc* 1994;85: 5227.
- Veber D F et al . Molecular properties that influence the oral bioavailability of drug candidates *J. Med. Chem* 2002; 45: 2615.
- Lee S K. Topomol V. Research Institute of Bioinformatics & Molecular Design(BMD), Seoul, Korea.*Korean Chem Soc* 1985; 2 :513.
- Lipinski CA et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv. Drug Deliv. Rev* 1997;23: 3.
- Gfeller D et al. Shaping the interaction landscape of bioactive molecules, *Bioinformatics* 2013; 29:3073-3079.
- Gfeller D et al . SwissTargetPrediction: a web server for target prediction of bioactive small molecules. *Nucleic Acids Res* 2014; 42.
- Gfeller D et al. A BOILED-Egg to predict gastrointestinal absorption and brain penetration of small molecules. *Chem. Med. Chem* 2016; 11(11): 1117-1121.
- Zoete V et al . SwissSimilarity: A Web Tool for Low to Ultra High Throughput Ligand-Based Virtual Screening., *J. Chem. Inf. Model* 2016; 56(8): 1399-1404.
- Teague S J et al . The Design of Leadlike Combinatorial Libraries *Angew. Chem. Int. Ed* 1999; 38: 3743.
- Ghose A K, Viswanadhan V N, Wendoloski J J. A Knowledge-Based Approach in Designing Combinatorial or Medicinal Chemistry Libraries for Drug Discovery. 1. A Qualitative and Quantitative Characterization of Known Drug Databases *J. Comb. Chem* 1999; 1: 55.
- Oprea T I. J. Property distribution of drug-related chemical databases *Comp. Aided Mol. Des* 2000; 14: 251.
- Kulkarni A, Han Y, Hopfinger A J. Predicting Caco-2 Cell Permeation Coefficients of Organic Molecules Using Membrane-Interaction QSAR Analysis *J. Chem. Inf. Comput. Sci* 2002; 42: 331
- Irvine J D et al. MDCK (Madin–Darby canine kidney) cells: A tool for membrane permeability screening *J. Pharm. Sci* 1999; 88: 28.
- John H. Rapidly resolving the pharmacokinetic and toxicological properties of drug candidates remains a key challenge for drug developers. *Nature Biotechnology* 2001; 19: 722-726.
- Dahlin J L, Inglesse J, Walters M A. Mitigating risk in academic preclinical drug discovery. *Nature Rev. Drug Discov* 2015; 14: 279–294 .
- Tian S *et al.* The application of in silico drug-likeness predictions in pharmaceutical research. *Adv. Drug. Deliv. Rev* 2015; 86: 2–10 .
- Clark A M *et al.* Open Source Bayesian Models. Application to ADME/Tox and Drug Discovery Datasets. *J. Chem. Inf. Model* 2015; 55: 1231–1245 .
- Pires D E et al. Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. *J. Med. Chem* 2015; 58: 4066–4072 .
- Daina A, Zoete V A. BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules. *Chem.Med.Chem* 2014; 11: 1117–1121.